CN105175545B - A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application - Google Patents
A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application Download PDFInfo
- Publication number
- CN105175545B CN105175545B CN201510692484.5A CN201510692484A CN105175545B CN 105175545 B CN105175545 B CN 105175545B CN 201510692484 A CN201510692484 A CN 201510692484A CN 105175545 B CN105175545 B CN 105175545B
- Authority
- CN
- China
- Prior art keywords
- vegf
- bifunctional antibody
- antibody
- seqidno
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000001588 bifunctional effect Effects 0.000 title claims abstract description 49
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 39
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 23
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 15
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 8
- 239000003814 drug Substances 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 9
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 108010074328 Interferon-gamma Proteins 0.000 claims description 6
- 101100463133 Caenorhabditis elegans pdl-1 gene Proteins 0.000 claims description 5
- 102100037850 Interferon gamma Human genes 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 3
- 238000009098 adjuvant therapy Methods 0.000 claims description 2
- 238000003745 diagnosis Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000028327 secretion Effects 0.000 abstract description 7
- 241000699670 Mus sp. Species 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 description 25
- 102100040678 Programmed cell death protein 1 Human genes 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 10
- 108010074708 B7-H1 Antigen Proteins 0.000 description 9
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 238000009169 immunotherapy Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000001962 electrophoresis Methods 0.000 description 6
- 239000013604 expression vector Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000027455 binding Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000012827 research and development Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229960003008 blinatumomab Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 210000001616 monocyte Anatomy 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 229940125644 antibody drug Drugs 0.000 description 2
- 229940120638 avastin Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229940101815 blincyto Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000000763 evoking effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 102000058223 human VEGFA Human genes 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000005374 membrane filtration Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 229960003301 nivolumab Drugs 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 229940118376 tetanus toxin Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101710184666 Ig gamma-2A chain C region Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102100040681 Platelet-derived growth factor C Human genes 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 108091007744 Programmed cell death receptors Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 1
- 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102100038217 Vascular endothelial growth factor B Human genes 0.000 description 1
- 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 1
- 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
- 101150030763 Vegfa gene Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012516 mab select resin Substances 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000037819 metastatic cancer Diseases 0.000 description 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229960002621 pembrolizumab Drugs 0.000 description 1
- 108010017992 platelet-derived growth factor C Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Kn(105M-1s-1) | Koff(10-5s-1) | Kd(nm) | |
BsAb7-PD-1 | 1.02 | 2.42 | 0.24 |
BsAb8-PD-1 | 0.96 | 2.33 | 0.24 |
BsAb7-VEGF | 1.44 | 2.10 | 0.15 |
BsAb8-VEGF | 1.89 | 2.31 | 0.12 |
Antibody concentration | OD450(BsAb7) | OD450(BsAb8) |
(stoste) 2 μ g/ml | 0.096 | 0.107 |
1:3 | 0.101 | 0.110 |
1:9 | 0.323 | 0.323 |
1:27 | 0.733 | 0.802 |
1:81 | 0.852 | 0.831 |
1:243 | 0.857 | 0.854 |
1:729 | 0.898 | 0.866 |
Control/0 | 0.901 | 0.899 |
Group | Average knurl weight (g) | Average tumour inhibiting rate (%) |
Negative control | 2.544±0.316 | / |
BsAb7 | 0.932±0.224 | 63.4 |
BsAb8 | 0.867±0.255 | 65.9 |
Avastin | 0.912±0.213 | 64.2 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510692484.5A CN105175545B (en) | 2015-10-20 | 2015-10-20 | A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510692484.5A CN105175545B (en) | 2015-10-20 | 2015-10-20 | A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105175545A CN105175545A (en) | 2015-12-23 |
CN105175545B true CN105175545B (en) | 2019-01-25 |
Family
ID=54898044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510692484.5A Active CN105175545B (en) | 2015-10-20 | 2015-10-20 | A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105175545B (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE046249T2 (en) | 2013-12-12 | 2020-02-28 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
WO2017165681A1 (en) * | 2016-03-24 | 2017-09-28 | Gensun Biopharma Inc. | Trispecific inhibitors for cancer treatment |
CN106977602B (en) * | 2016-08-23 | 2018-09-25 | 中山康方生物医药有限公司 | A kind of anti-PD1 monoclonal antibodies, its medical composition and its use |
CN106967172B (en) | 2016-08-23 | 2019-01-08 | 康方药业有限公司 | The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use |
WO2018035710A1 (en) | 2016-08-23 | 2018-03-01 | Akeso Biopharma, Inc. | Anti-ctla4 antibodies |
CA3035681A1 (en) | 2016-09-29 | 2018-04-05 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
PE20191080A1 (en) | 2016-11-18 | 2019-08-20 | Beijing Hanmi Pharmaceutical Co Ltd | STRUCTURAL HETERODIMERIC BIESPECIFIC ANTIBODY OF ANTI-PD-1 / ANTI-HER2 NATURAL ANTIBODY AND METHOD TO PREPARE THE SAME |
JP7274426B2 (en) * | 2017-05-16 | 2023-05-16 | ブリストル-マイヤーズ スクイブ カンパニー | Treatment of cancer with anti-GITR agonist antibodies |
TW201902514A (en) * | 2017-06-05 | 2019-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | Use of PD-1 antibody in combination with VEGF ligand or VEGF receptor inhibitor for the preparation of a medicament for treating tumor |
CN107383174B (en) * | 2017-08-21 | 2019-01-18 | 生工生物工程(上海)股份有限公司 | A kind of tumor suppression peptide and application thereof that can be specifically bound with PD-1 |
CN109575140B (en) * | 2017-09-29 | 2021-02-23 | 北京比洋生物技术有限公司 | Dual-targeting fusion proteins targeting PD-1 or PD-L1 and targeting the VEGF family and uses thereof |
WO2019153200A1 (en) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | Anti-pd-1/anti-her2 natural antibody structure-like bispecific antibody in heterodimeric form and preparation thereof |
KR20200120927A (en) * | 2018-02-11 | 2020-10-22 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Anti-PD-1/anti-VEGF natural antibody structure-like heterodimeric bispecific antibody and preparation thereof |
CN109053895B (en) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | Bifunctional antibody for resisting PD-1-VEGFA, pharmaceutical composition and application thereof |
CN109942712B (en) * | 2019-04-01 | 2022-12-20 | 华博生物医药技术(上海)有限公司 | anti-PD-L1/VEGF bifunctional antibody and application thereof |
CN110498857B (en) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | anti-VEGF-anti-PD 1 bispecific antibody |
CN110563849B (en) * | 2019-08-09 | 2022-09-09 | 安徽瀚海博兴生物技术有限公司 | anti-VEGF-anti-PD 1 bispecific antibody |
DE112019005626T5 (en) * | 2019-08-09 | 2021-08-05 | Anhui Biox Vision Biological Technology Co., Ltd. | Anti-VEGF-Anti-PD1 bispecific antibody with a new structure |
CA3162748A1 (en) * | 2019-11-25 | 2021-06-03 | Akeso Biopharma, Inc. | Anti-pd-1-anti-vegfa bispecific antibody, pharmaceutical composition and use thereof |
JP2024513205A (en) * | 2021-03-31 | 2024-03-22 | ウーシー バイオロジクス アイルランド リミテッド | Bispecific anti-PD-L1/VEGF antibodies and their uses |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945508A (en) * | 2007-06-18 | 2015-09-30 | 默沙东有限责任公司 | Antibodies to human programmed death receptoR PD-1 |
CN104974260A (en) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | Anti-HGF/VEGF bispecific antibody as well as preparation method and application thereof |
-
2015
- 2015-10-20 CN CN201510692484.5A patent/CN105175545B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104945508A (en) * | 2007-06-18 | 2015-09-30 | 默沙东有限责任公司 | Antibodies to human programmed death receptoR PD-1 |
CN104974260A (en) * | 2014-04-01 | 2015-10-14 | 上海中信国健药业股份有限公司 | Anti-HGF/VEGF bispecific antibody as well as preparation method and application thereof |
Non-Patent Citations (2)
Title |
---|
PD-1-VEGF 多靶向Fc 融合蛋白PVP 的表达、纯化及初步功能研究;王倩;《中国优秀硕士学位论文全文数据库》;20131215;全文 |
Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor2(VEGFR2) induces synergistic anti-tumor effect in vivo;Yasuda S et al;《Clinical & Experimental Immunology》;20131231;500-506 |
Also Published As
Publication number | Publication date |
---|---|
CN105175545A (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105175545B (en) | A kind of anti-PD-1 bifunctional antibody of anti-vegf-and its application | |
AU2020255712B2 (en) | Anti-PD-L1/VEGF bifunctional antibody and use thereof | |
CN106967172B (en) | The anti-PD-1 bifunctional antibody of anti-CTLA 4-, its medical composition and its use | |
JP6636066B2 (en) | Antibodies targeting both human p185 and vascular endothelial growth factor and applications thereof | |
JP7262597B2 (en) | Bispecific antibodies and methods of making and using the same | |
CN105121474B9 (en) | Fusion immunomodulatory protein and preparation method thereof | |
WO2022121239A1 (en) | Bispecific antibody and application thereof | |
CA3084391C (en) | A bifunctional fusion protein targeting cd47 and pd-l1 | |
JP2023052397A (en) | Chimeric antigen receptors against axl or ror2 and methods for use thereof | |
CN105296433A (en) | CTLA4 antibody, pharmaceutical composition thereof and application of pharmaceutical composition | |
CN104628866B (en) | A kind of targeting VEGFR2 preparation of antibody fusion protein and application thereof | |
CN106117366A (en) | A kind of CD19 specific chimeric antigen receptor and encoding gene, application | |
CN106554416B (en) | A kind of application of anti-PD-L1 Humanized monoclonal antibodies joint interferon gene stimulates the protein (STING) agonist in antitumor | |
US20230183352A1 (en) | Bispecific antibody targeting human claudin and human pdl1 proteins, and application thereof | |
WO2021219127A1 (en) | Bispecific antibody targeting her2 and pd-1 and application thereof | |
CN102241774A (en) | Recombinant IgE-Fc-anti EGFR single chain variable fragment fusion protein, its preparation method and its application | |
TW202229353A (en) | Anti-TSPAN8-anti-CD3 Bispecific Antibody and Anti-TSPAN8 Antibody | |
CN110437340A (en) | Double target spots identify the preparation method of controllable engineering immunocyte | |
CN115335407A (en) | Chimeric antigen receptor binding to CD19 and uses thereof | |
CN104059148A (en) | Humanized anti human epidermal growth factor receptor antibody and application thereof | |
US20220119540A1 (en) | Humanized anti-human ox40 monoclonal antibody, preparation method therefor and use thereof | |
CN117222672A (en) | anti-CLDN 4-anti-CD 137 bispecific antibodies | |
CN111848806B (en) | EGFR-CD3 bifunctional antibody and application thereof | |
CN105713094B (en) | A kind of design and its application of CD24 antibody fusion protein | |
CN101619305B (en) | Antihuman CD52 monoclonal antibody hybridoma cell line, monoclonal antibody, engineered antibody, carrier, reagent kit and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151223 Assignee: Anhui Xingtai Financial Leasing Co.,Ltd. Assignor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2021340000011 Denomination of invention: A bifunctional antibody against vegf-pd-1 and its application Granted publication date: 20190125 License type: Exclusive License Record date: 20210609 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A bifunctional antibody against vegf-pd-1 and its application Effective date of registration: 20210616 Granted publication date: 20190125 Pledgee: Anhui Xingtai Financial Leasing Co.,Ltd. Pledgor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021980004776 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220718 Granted publication date: 20190125 Pledgee: Anhui Xingtai Financial Leasing Co.,Ltd. Pledgor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Registration number: Y2021980004776 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Anhui Xingtai Financial Leasing Co.,Ltd. Assignor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2021340000011 Date of cancellation: 20220801 |
|
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20151223 Assignee: Anhui Xingtai Financial Leasing Co.,Ltd. Assignor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023980035207 Denomination of invention: A Bifunctional Antibody Against VEGF and PD-1 and Its Application Granted publication date: 20190125 License type: Exclusive License Record date: 20230508 |
|
EE01 | Entry into force of recordation of patent licensing contract | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A Bifunctional Antibody Against VEGF and PD-1 and Its Application Effective date of registration: 20230509 Granted publication date: 20190125 Pledgee: Anhui Xingtai Financial Leasing Co.,Ltd. Pledgor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023980040122 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20190125 Pledgee: Anhui Xingtai Financial Leasing Co.,Ltd. Pledgor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Registration number: Y2023980040122 |
|
EC01 | Cancellation of recordation of patent licensing contract | ||
EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Anhui Xingtai Financial Leasing Co.,Ltd. Assignor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Contract record no.: X2023980035207 Date of cancellation: 20240612 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A bifunctional antibody against VEGF and PD-1 and its application Granted publication date: 20190125 Pledgee: Hefei Xingtai Technology Micro-loan Co.,Ltd. Pledgor: ANHUI RUBIOX-VISION BIOTECHNOLOGY Co.,Ltd. Registration number: Y2024980024081 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |